Melanoma is a tumor of the melanocytes whose tissue of origin is primarily the skin, although it may also develop occasionally in the: gastrointestinal, genitourinary, or respiratory tracts; ocular or mucosal tissue; or meninges. It is subcategorized into superficial spreading melanoma (70% of cases), nodular melanoma (15-30%), lentigo maligna melanoma (10%-20%), and acral lentiginous melanoma (5%). Risk factors include a positive personal or family history of melanoma, genetic predisposition, and exposure to ultraviolet light.Diagnosis is made by excisional, incisional, or punch skin biopsy while imaging or indirect ophthalmoscopy may be employed to diagnose uveal or choroidal melanoma.The seventh most common cancer in the U.S., it has an annual incidence of over 76,000.
In this online CME self-learning program:
Faculty introduction, disclosures
Introduction content: cursory refresher and review
Emerging immuno- and monoclonal therapy in melanoma
Summary, conclusions, and best practice recap
The following healthcare professionals: oncologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with malignant melanoma.
This program is supported by educational grants from Prometheus.
Release Date: December 04, 2017 -- Expiration Date: December 04, 2019
Faculty: Diwakar Davar , MD
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Diwakar Davar, MD, Assistant Professor, Melanoma and Phase I Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, PA has received grants and/or serves as a consultant to Merck and Incyte Pharmaceuticals.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, CEO of ScientiaCME has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by educational grants from Prometheus.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Basal Cell Carcinoma (BCC): Therapeutic Updates, Best Practices, and the Role of Personalized Patient Care